Clinical Trials
7 trialsNCT04751383 2026-01-21
Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma
National Cancer Institute (NCI)
Phase 1 Completed
NCT05169944 2025-07-09
PNOC025
University of California, San Francisco
Phase 1 Completed
NCT04599634 2025-02-04
Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT03558139 2024-04-01
Study of Magrolimab (Hu5F9-G4) in Combination With Avelumab in Solid Tumor Participants and Checkpoint-Inhibitor-Naive Ovarian Cancer Participants Who Progress Within 6 Months of Prior Platinum Chemotherapy
Gilead Sciences
Phase 1 Completed
NCT03527147 2022-08-15
PRISM
Acerta Pharma BV
Phase 1 Completed
NCT02678338 2019-02-21
CAMELLIA: Anti-CD47 Antibody Therapy in Haematological Malignancies
Gilead Sciences
Phase 1 Completed
NCT02216409 2019-02-05
Phase 1 Trial of Hu5F9-G4, a CD47-targeting Antibody
Gilead Sciences
Phase 1 Completed